Did You Suffer Financial Losses Investing in Better Home & Finance Holding Company (BETR)?

A securities class action has been filed on behalf of persons and entities that purchased or otherwise acquired Better Home & Finance Holding Company (“Better Home” or the “Company”) (NASDAQ: BETR) securities between March 13, 2026 and May 7, 2026, inclusive (the “Class Period”).

The action, Gastwirt v. Better Home & Finance Holding Company, et al., Case No. 1:26-cv-08219, was filed on September 21, 2026 in the United States District Court for the Southern District of New York. The complaint asserts claims under the federal securities laws.

What Does the Better Home Class Action Allege?

According to the complaint, during the Class Period, defendants made materially false and/or misleading statements and failed to disclose that Better Home’s conversion funnel was already slowing due to macro factors and that, as a result, the Company’s $1 billion monthly funded volume target was likely to be deferred. The complaint alleges that defendants’ positive statements about Better Home’s business, operations, and prospects were, therefore, materially misleading and/or lacked a reasonable basis.

According to the complaint, on May 7, 2026, Better Home reported first-quarter 2026 results and provided second-quarter loan-volume guidance of $1.575 billion to $1.725 billion. During an earnings call that day, Chief Executive Officer Vishal Garg stated that conversion rates were down from the first quarter due to macro factors, customers were “not converting at nearly the same rate,” and the timing of the Company’s $1 billion monthly funded volume target looked likely to be deferred.

On this news, Better Home’s stock price fell $12.17, or 28.5%, to close at $30.52 per share on May 7, 2026, on unusually heavy trading volume.

November 20, 2026 Lead Plaintiff Deadline

Investors who purchased or otherwise acquired Better Home securities during the Class Period have until November 20, 2026 to move the Court to seek appointment as lead plaintiff. Investors do not need to seek appointment as lead plaintiff to remain a member of the proposed class.

Better Home Investors: Contact Kehoe Law Firm

If you purchased or otherwise acquired Better Home securities during the Class Period and suffered financial losses, you are encouraged to complete Kehoe Law Firm’s confidential Stockholder Information Request Form or send us a message to learn more about the class action and your potential legal rights.

For a free, no-obligation legal evaluation, contact:

Michael Yarnoff, Esq.
(215) 792-6676, Ext. 804
[email protected]
[email protected]

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action law firm representing investors, consumers, and employees in matters involving securities fraud, corporate misconduct, mergers and acquisitions, antitrust violations, whistleblower claims, data breaches, consumer fraud, employment law violations, and retirement-plan mismanagement. Its attorneys have served as lead or co-lead counsel in major securities cases, recovering more than $10 billion for institutional and individual investors.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning plaintiffs are not responsible for attorneys’ fees or litigation expenses. Any request for attorneys’ fees and expenses will be subject to court approval.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Did You Lose Money Investing in Endava (DAVA) American Depositary Shares (“ADS”)?

Kehoe Law Firm, P.C. is investigating potential securities fraud claims on behalf of investors of Endava plc (“Endava” or the “Company”) (NYSE: DAVA).

Class Action Complaint Filed Against Endava

On September 29, 2026, a class action complaint was filed on behalf of persons and entities that purchased or otherwise acquired Endava securities between September 4, 2025 and September 21, 2026, both dates inclusive (the “Class Period”). 

The action, Laguna v. Endava plc, et al., was filed in United States District Court for the Southern District of New York, Case No. 1:26-cv-08556, and pursues claims against the Defendants under the Securities Exchange Act of 1934. 

Alleged Violations

According to the complaint, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.

Specifically, Defendants failed to disclose to investors that 1) the accounting treatment for certain customer and supplier agreements and related matters required additional review; 2) the Company would delay the release of its fourth quarter and full year 2026 financial results; 3) there was reason to doubt the effectiveness of the Company’s internal controls and procedures; and 4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Endava Announces Investigation Into Accounting Treatment

On September 21, 2026, after the market closed, Endava announced that Chief Financial Officer Mark Thurston had been placed on administrative leave pending the conclusion of an ongoing investigation being conducted by independent outside counsel for the Board’s Audit Committee.

According to the complaint, the investigation was initiated in response to “concerns about the Company’s accounting treatment of certain customer and supplier agreements and related matters.”

The complaint alleges that, on this news, the price of Endava’s ADS fell $0.68 per share, or 24.37%, to close at $2.11 per share on September 22, 2026, on unusually heavy trading volume.

November 30, 2026 Lead Plaintiff Deadline: Endava investors who acquired their securities during the Class Period have until November 30, 2026 to move the Court to seek appointment as lead plaintiff. Investors do not need to seek appointment as lead plaintiff to remain a member of the proposed class.

Endava Investors: Contact Kehoe Law Firm

If you acquired Endava securities during the Class Period and suffered financial losses, you are encouraged to complete Kehoe Law Firm’s confidential Stockholder Information Request Form or send us a message to learn more about the investigation and your potential legal rights.

For a free, no-obligation legal evaluation, contact:

Michael Yarnoff, Esq.
(215) 792-6676, Ext. 804
[email protected]
[email protected]

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action law firm representing investors, consumers, and employees in matters involving securities fraud, corporate misconduct, mergers and acquisitions, antitrust violations, whistleblower claims, data breaches, consumer fraud, employment law violations, and ERISA and retirement plan litigation. Its attorneys have served as lead or co-lead counsel in major securities cases, recovering more than $10 billion for institutional and individual investors.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning plaintiffs are not responsible for attorneys’ fees or litigation expenses. Any request for attorneys’ fees and expenses will be subject to court approval.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Did You Acquire Blaize Common Stock Between July 17, 2025 and August 13, 2026 or Pursuant or Traceable to the Offering Materials Issued in Connection with Blaize’s May 2026 Public Offering?

A securities class action has been filed on behalf of all persons and entities who purchased or otherwise acquired Blaize Holdings, Inc. (“Blaize” or the “Company”) (NASDAQ: BZAI) common stock between July 17, 2025 and August 13, 2026, inclusive (the “Class Period”) and all persons and entities who purchased or otherwise acquired Blaize common stock pursuant or traceable to the Offering Materials issued in connection with Blaize’s May 2026 public offering.

The action, Alyahya v. Blaize Holdings, Inc., et al., Case No. 2:26-cv-10609, was filed on September 17, 2026 in the U.S. District Court for the Central District of California. The action asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, and Sections 11, 12(a)(2), and 15 of the Securities Act of 1933.

What Does the Complaint Allege?

The complaint alleges that Defendants made materially false and/or misleading statements concerning Blaize’s agreements with Starshine Computing Power Technology Limited and NeoTensr and the extent to which those agreements supported Blaize’s revenue projections.

Specifically, the complaint alleges that: (1) Starshine was an unproven counterparty and there was substantial uncertainty whether it had the resources and operational capacity to fully perform under the Starshine agreement; (2) there was substantial uncertainty whether NeoTensr had the resources and operational capacity to issue purchase orders sufficient to generate the anticipated $50 million in first-year revenue; (3) as of March 31, 2026, 53% of Blaize’s accounts receivable were more than 90 days past due and two customers located in China, with subsequent disclosures indicating that those customers were Starshine and NeoTensr, accounted for approximately 93.3% of the Company’s accounts receivable; (4) Blaize had not secured the inventory needed for an anticipated NeoTensr delivery despite statements concerning that inventory; and (5) as a result, Defendants allegedly lacked a reasonable basis for representing that Blaize would achieve its full-year 2026 revenue guidance.

The complaint further alleges that the offering materials for Blaize’s May 2026 public offering contained materially inaccurate statements and omissions concerning Blaize’s receivables and the Starshine and NeoTensr agreements, including that Blaize had not secured the inventory needed for the anticipated NeoTensr delivery. In the offering, Blaize sold 18,918,918 shares of common stock at $1.85 per share.

BZAI Stock Declines Following August 13 Disclosure

The complaint alleges that the truth was finally revealed after the market closed on August 13, 2026, when Blaize reduced its full-year 2026 revenue outlook from $130 million to $40-$43 million, citing commercial opportunities that did not convert into orders and higher supply-chain costs. Blaize also disclosed that Starshine’s $8.8 million receivable remained outstanding and that it did not expect further purchase orders from Starshine.

According to the complaint, Blaize common stock fell from $1.17 per share on August 13, 2026 to $0.59 per share on August 14, 2026, a decline of nearly 50% in one day.

October 5, 2026 Lead Plaintiff Deadline

The deadline to seek appointment as lead plaintiff is October 5, 2026. You do not need to seek appointment as lead plaintiff to remain a member of the proposed class.

Blaize Investors: Contact Kehoe Law Firm

If you purchased or otherwise acquired Blaize common stock during the Class Period or pursuant or traceable to the May 2026 public offering, and suffered financial losses, you are encouraged to complete Kehoe Law Firm’s confidential Stockholder Information Request Form or send us a message to discuss your potential legal rights.

For a free, no-obligation legal evaluation, contact:

Michael Yarnoff, Esq.
(215) 792-6676, Ext. 804
[email protected]
[email protected]

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action law firm representing investors, consumers, and employees in matters involving securities fraud, corporate misconduct, mergers and acquisitions, antitrust violations, whistleblower claims, data breaches, consumer fraud, employment law violations, and retirement-plan mismanagement. Its attorneys have served as lead or co-lead counsel in major securities cases, recovering more than $10 billion for institutional and individual investors.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning plaintiffs are not responsible for attorneys’ fees or litigation expenses. Any request for attorneys’ fees and expenses will be subject to court approval.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Did You Purchase or Otherwisw Acquire Ardelyx Common Stock Between January 13, 2025 and August 6, 2026?

A securities class action has been filed on behalf of investors who purchased or otherwise acquired Ardelyx, Inc. (“Ardelyx” or the “Company”)(NASDAQ: ARDX) common stock between January 13, 2025 and August 6, 2026, inclusive (the “Class Period”).

The action, Broadwater v. Ardelyx, Inc., et al., Case No. 1:26-cv-14270, was filed on September 17, 2026 in the U.S. District Court for the District of Massachusetts. The action asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

What Does the Complaint Allege?

The complaint alleges that Defendants made positive statements about Ardelyx’s commercial growth and its ability to achieve projected revenue guidance and long-term growth targets for IBSRELA and XPHOZAH while making materially false and misleading statements and/or concealing material adverse facts concerning the true state of the products’ commercial performance and growth prospects.

Specifically, the complaint alleges that Ardelyx was facing increasing payer-related access and reimbursement barriers, including more stringent prior authorization requirements and step-edit requirements, that slowed new-patient starts and delayed prescription fulfillment. The complaint further alleges that Defendants continued to tout commercial growth and sustained product demand while minimizing increasing payer and access hurdles affecting IBSRELA and uncertainty surrounding XPHOZAH’s ability to achieve its long-term growth targets.

ARDX Stock Declines Following August 6 Disclosure

The complaint alleges that the truth emerged after the market closed on August 6, 2026, when Ardelyx reported that IBSRELA revenue was below expectations due to significantly increased utilization-management processes from payors. Ardelyx cut its full-year 2026 IBSRELA revenue guidance from $410-$430 million to $350-$370 million and withdrew its long-term XPHOZAH revenue guidance.

According to the complaint, Ardelyx’s common stock fell from a closing price of $4.87 per share on August 6, 2026 to $4.00 per share on August 7, 2026, a decline of approximately 18% in one day.

November 16, 2026 Lead Plaintiff Deadline

The deadline to seek appointment as lead plaintiff is November 16, 2026. You do not need to seek appointment as lead plaintiff to remain a member of the proposed class.

Ardelyx Investors: Contact Kehoe Law Firm

If you purchased or otherwise acquired Ardelyx common stock during the Class Period and suffered financial losses, you are encouraged to complete Kehoe Law Firm’s confidential Stockholder Information Request Form or send us a message to discuss your potential legal rights.

For a free, no-obligation legal evaluation, contact:

Michael Yarnoff, Esq.
(215) 792-6676, Ext. 804
[email protected]
[email protected]

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action law firm representing investors, consumers, and employees in matters involving securities fraud, corporate misconduct, mergers and acquisitions, antitrust violations, whistleblower claims, data breaches, consumer fraud, employment law violations, and retirement-plan mismanagement. Its attorneys have served as lead or co-lead counsel in major securities cases, recovering more than $10 billion for institutional and individual investors.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning plaintiffs are not responsible for attorneys’ fees or litigation expenses. Any request for attorneys’ fees and expenses will be subject to court approval.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]